American Journal of Ophthalmology
Volume 141, Issue 1 , Pages 54-61.e1, January 2006

Microdissection Genotyping Analysis of the Effect of Intraarterial Cytoreductive Chemotherapy in the Treatment of Lacrimal Gland Adenoid Cystic Carcinoma

  • David T. TSE, MD

      Affiliations

    • Department of Ophthalmology, University of Miami Miller School of Medicine, Miami, Florida
    • Corresponding Author InformationInquiries to David T. Tse, MD, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, 900 NW 17th Street, Miami, FL 33136; fax: (305) 326-6443
  • ,
  • Sydney D. Finkelstein, MD

      Affiliations

    • RedPath Integrated Pathology Inc, Pittsburgh, Pennsylvania
  • ,
  • Pasquale Benedetto, MD

      Affiliations

    • Department of Internal Medicine, University of Miami Miller School of Medicine, Miami, Florida
  • ,
  • Sander Dubovy, MD

      Affiliations

    • Department of Ophthalmology, University of Miami Miller School of Medicine, Miami, Florida
  • ,
  • Joyce Schiffman, MS

      Affiliations

    • Department of Ophthalmology, University of Miami Miller School of Medicine, Miami, Florida
  • ,
  • William J. Feuer, MS

      Affiliations

    • Department of Ophthalmology, University of Miami Miller School of Medicine, Miami, Florida

Accepted 1 September 2005. published online 11 November 2005.

Purpose

To investigate the feasibility of integrating molecular analysis into standard histopathology for lacrimal gland adenoid cystic carcinoma (ACC), and to gain insights into the molecular pathogenesis of this tumor and its response to intraarterial cytoreductive chemotherapy (IACC) that is of clinical use.

Design

A retrospective, comparative case series.

Methods

setting: Institutional. patient population: Nine consecutive patients with lacrimal gland ACC were treated with IACC, followed by orbital exenteration and chemoradiotherapy. This case series was compared with a series of seven patients treated by conventional local therapies. intervention procedure: Gene analysis was performed on microdissected tissue samples. Mutational allelotyping targeting nine genomic loci was performed with 15 polymorphic microsatellite markers situated in proximity to known tumor suppressor genes serving as markers for the presence of gene deletion. main outcome measure: A fractional mutation index was used to compare the acquired mutational load between different tumors having nonidentical patterns of microsatellite informativeness.

Results

Allelic imbalance (loss of heterozygosity [LOH]) for microsatellite markers at 1p36 was the single most common site affected by imbalance in this series, followed by LOH in temporal sequence involving 9p21, 22q12, 10q23, and 9q22.

Conclusions

Microdissection genotyping holds promise as a clinical tool in integrating molecular analysis into standard histopathology to advance the understanding of lacrimal gland ACC tumorigenesis. A unique time course for temporal mutation acquisition in ACC is proposed, consisting of 1p36 loss first. Allelic loss for microsatellite markers at 1p36 may be a common as well as an early event in ACC formation and progression.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 See accompanying Article on page 44 and Brief Report on page 187.Supported in part by NIH center grant P30-EY014801; an unrestricted grant from Research to Prevent Blindness Inc, New York, New York, and a grant from the Plum Foundation, Los Angeles, California.This manuscript is based on a thesis that was prepared in partial fulfillment of the requirements for membership in the American Ophthalmological Society.

PII: S0002-9394(05)01010-X

doi:10.1016/j.ajo.2005.09.002

American Journal of Ophthalmology
Volume 141, Issue 1 , Pages 54-61.e1, January 2006